Calcinosis cutis universalis with pediatric systemic lupus erythematosus.
Dönmez
Osman
O
Durmaz
Oguzhan
O
D000284:Administration, Oral; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D001241:Aspirin / Q000627:therapeutic use; D002114:Calcinosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004110:Diltiazem / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D012883:Skin Ulcer / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome
D003879:Dermatologic Agents; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D005938:Glucocorticoids; D016572:Cyclosporine; D004110:Diltiazem; D001241:Aspirin